Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
Do immune checkpoint inhibitors affect COVID-19 severity?
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage IIIA and B NSCLC
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines
Positive preliminary results for combination therapy with adagrasib in KRAS G12C-mutated NSCLC
Phase III trials are planned to assess combined KRAS G12C inhibition/checkpoint inhibition as first-line therapy